Dimerix (ASX:DXB) may receive "commercial incentives" if its ongoing clinical trial on its DMX-200 drug for focal segmental glomerulosclerosis, a form of kidney disease, becomes successful, Euroz Hartleys said in a Thursday note.
The biotechnology firm opened its first pediatric site for the trial in Mexico, with 14 other pediatric sites set to open in the UK, the US, Argentina, and Brazil.
The investment firm said that if the pediatric segment of the study becomes successful, the drugmaker may be able to market and sell the medication to both pediatric and adult patients in key global markets, including Europe and the US.
Euroz Hartleys maintained its speculative buy rating and AU$0.86 price target on Dimerix.
Dimerix shares fell past 4% in recent Friday trade.
Price (AUD): $0.42, Change: $-0.02, Percent Change: -4.14%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.